This work emphasizes the advantages of CD73 inhibition for preventing CRC cell malignancies and regaining anti-tumor CD8+ T cell activities, hence presenting unique and efficient approaches for upcoming clinical trials of refractory CRCs. The gene discussed is CD8A; the disease is neoplasm.